1. Home
  2. NBIX vs EXEL Comparison

NBIX vs EXEL Comparison

Compare NBIX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$156.33

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Logo Exelixis Inc.

EXEL

Exelixis Inc.

HOLD

Current Price

$52.12

Market Cap

11.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBIX
EXEL
Founded
1992
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
11.4B
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
NBIX
EXEL
Price
$156.33
$52.12
Analyst Decision
Strong Buy
Buy
Analyst Count
22
21
Target Price
$180.91
$46.50
AVG Volume (30 Days)
1.0M
2.2M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
41.95
57.95
EPS
1.91
0.79
Revenue
$161,626,000.00
$452,477,000.00
Revenue This Year
$24.73
$13.61
Revenue Next Year
$13.14
$13.13
P/E Ratio
$83.51
$67.09
Revenue Growth
977.51
N/A
52 Week Low
$122.14
$33.76
52 Week High
$169.57
$53.93

Technical Indicators

Market Signals
Indicator
NBIX
EXEL
Relative Strength Index (RSI) 50.17 57.89
Support Level $153.30 $40.17
Resistance Level $160.08 N/A
Average True Range (ATR) 5.25 1.56
MACD -1.33 -0.04
Stochastic Oscillator 14.33 73.05

Price Performance

Historical Comparison
NBIX
EXEL

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Share on Social Networks: